Zoetis (ZTS) Stock
Global animal health leader for pets and livestock. Here's the price, business snapshot, and what's worth knowing about Zoetis in October 2026.
Zoetis Inc. (ZTS) is a global leader in animal health, developing, manufacturing and commercialising medicines, vaccines and diagnostics for livestock and companion animals. With a market capitalisation of about $64.7bn, the company benefits from steady, recurring demand driven by pet ownership trends, livestock productivity needs and veterinary services growth across developed and emerging markets. Zoetis' strength lies in a diversified product portfolio, a broad geographic footprint and ongoing investment in R&D and targeted acquisitions to expand its pipeline. Investors should note potential advantages — predictable cash flows, margin resilience and dividend capacity — alongside risks such as regulatory scrutiny, pricing pressures, disease outbreaks and currency exposure. Zoetis may suit investors seeking exposure to defensive growth within healthcare, but it is important to assess valuation, portfolio fit and risk tolerance. This information is educational only and not personalised investment advice; values can rise or fall and past performance is not a guarantee of future returns.
Why It’s Moving
Zoetis Shares Dip Amid Broader Market Gains as Analysts Eye Long-Term Recovery
- Shares closed at $69.10, reflecting a -1.05% change compared to the previous close, indicating short-term weakness even as the wider market advanced.
- The stock has fallen approximately 71% from its 2021 peak, driven by eroded pricing power and declining pet medicine volumes, though it currently trades at valuations seen in 2017.
- Analysts highlight that while patent expiries for key drugs like Apoquel and Simparica pose risks in 2030/2032, a robust pipeline of 12 candidates could offset revenue losses if half succeed.
Zoetis Shares Dip Amid Broader Market Gains as Analysts Eye Long-Term Recovery
- Shares closed at $69.10, reflecting a -1.05% change compared to the previous close, indicating short-term weakness even as the wider market advanced.
- The stock has fallen approximately 71% from its 2021 peak, driven by eroded pricing power and declining pet medicine volumes, though it currently trades at valuations seen in 2017.
- Analysts highlight that while patent expiries for key drugs like Apoquel and Simparica pose risks in 2030/2032, a robust pipeline of 12 candidates could offset revenue losses if half succeed.
Sixth Month Growth Performance
When is the next earnings date for ZOETIS INC (ZTS)?
Zoetis has a confirmed upcoming earnings report scheduled for November 5, 2026, at 8:30 AM Eastern Time before the market opens. This release will cover the company's third-quarter fiscal results for the period ending in late September 2026. Investors should note that this date aligns with Zoetis' historical pattern of reporting quarterly results approximately three months after the previous announcement.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Zoetis stock, with a target price suggesting significant potential for growth.
Financial Health
Zoetis is generating strong profits and cash flow, reflecting healthy business performance and demand.
Dividend
Zoetis Inc's dividend yield of 2.96% is decent for those seeking dividend income. If you invested $1000, you would be paid $29.60 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Steady demand drivers
Rising pet ownership and livestock productivity needs can support predictable revenue, though sales can vary with animal health trends and outbreaks.
Global footprint
A wide geographic reach exposes Zoetis to growth in emerging markets, but also brings currency and regulatory risk across regions.
R&D and pipeline
Ongoing investment in R&D and selective acquisitions fuels future products, yet new launches carry execution and approval risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
